Patients with cancers of the gullet, stomach and bowel respond well to new anti-HER2 drug

November 14, 2018, ECCO-the European CanCer Organisation

Dublin, Ireland: An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block the growth of cancer cells has shown promising signs of anti-tumour activity in a number of cancers including those of the gullet (oesophagus), stomach and bowel.

Results from the phase I clinical trial of the drug, called ZW25, had been presented earlier this year, but updated results, focusing on with oesophageal, stomach, bowel and several other cancers driven by HER2, were presented today at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.

HER2, a member of the human epidermal growth factor receptor family, is best known for the role it plays in breast cancer. Trastuzumab (Herceptin) is an effective treatment for HER2?positive breast cancers. Stomach cancers that are driven by HER2 also respond well to trastuzumab, but if the cancer returns in these patients, there are no further approved HER2?targeted agents. Unfortunately, for patients with other HER2?driven cancers, there are currently no approved HER2?targeted agents.

Dr. Murali Beeram, a medical oncologist and clinical investigator at the START Center for Cancer Care, San Antonio, USA, told the Symposium that as of 16 October a total of 24 patients, who had received several previous therapies (an average of four) but whose cancers had returned, have been given between one and ten cycles of ZW25 since joining the phase I trial, which started in September 2016 (either 10 mg/kg weekly or 20 mg/kg every other week). All had HER2 positive cancers, including cancers of the oesophagus and stomach (gastroesophageal) (10 patients), bowel (5), gall bladder (3), bile duct (1), cervix (1), endometrial (1) fallopian tube (1), skin (adnexal) (1), and parotid gland (1), and eight of these patients remain in the trial.

The latest results in 17 patients with responses available for evaluation show that 13 experienced shrinkage of their tumour. The median time the patients survived without their disease progressing was 6.21 months. Side effects have been mostly mild or moderate with the most common being diarrhoea or a reaction to the infusion of the drug.

Dr. Beeram said: "As a clinician, I am excited by the single agent anti-tumour activity and tolerability we are seeing with ZW25, particularly in these patents with advanced HER2?expressing cancers that have progressed after multiple prior therapies, including HER2?targeted agents. In fact, trastuzumab is the only HER2?targeted therapy approved for gastric cancer and there are no approved HER2-targeted therapies for other types of cancer that are driven by the HER2 receptor. ZW25 has been well tolerated to date, which should allow it to be used in combination with other agents for potentially even better responses."

ZW25 is an antibody that can simultaneously bind two distinct regions of the HER2 receptor, a protein that promotes the growth of cancer cells. Dr. Beeram explained: "This unique design results in multiple mechanisms of action, including dual HER2 signal blockade, increased binding, and removal of HER2 protein from the cancer cell surface; it also stimulates the immune system to attack the cancer cells. This has led to encouraging anti-tumour activity in patients whose tumours have stopped responding to approved therapies, and who are in desperate need of new medicines that provide anti-tumour activity without excessive toxic side effects. The impressive activity of ZW25, combined with its tolerability, is notable and should be investigated further."

In addition to the cancers already mentioned, a number of others also are driven by the HER2 protein; they include cancers of the womb, ovaries, lung and bladder. Zymeworks, the company that developed ZW25, has expanded the study and a phase II/III study for patients with oesophageal, stomach, and other cancers is planned for next year. In addition, studies are planned to investigate ZW25 in combination with other anti- drugs in patients with cancers that have an overabundance of HER2 receptors and copies of the HER2 gene, and also in those with fewer HER2 receptors and gene copies.

Co-chair of the EORTC-NCI-AACR Symposium, Professor Antoni Ribas from the University of California Los Angeles, who was not involved in the research, commented: "Although these are early results on a small number of patients, they suggest that this new HER2 targeted antibody can have an effect on difficult-to-treat cancers that have either failed to respond to previous therapies or have recurred. We look forward to further results from this study, as well as the further studies that are planned."

Explore further: Will tarloxotinib finally break the HER2 barrier in lung cancer?

More information: Abstract no: 6, "Single agent activity of ZW25, a HER2-targeted bispecific antibody, in HER2-expressing gastroesophageal and other cancers". Proffered papers, plenary session 2, Auditorium, 14.30 hrs, Wednesday 14 November.

Related Stories

Will tarloxotinib finally break the HER2 barrier in lung cancer?

November 7, 2018
The HER2 gene is a well-known driver of breast cancer, where changes in this gene are found in about 1-in-5 cases of the disease. HER2 also contributes to about 3 percent of lung cancers, representing about 6,500 patients ...

Promising clinical trial results of tucatinib with T-DM1 against HER2+ breast cancer

July 10, 2018
Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib (formerly ONT-380) with T-DM1 against heavily pretreated HER2-positive breast cancer. Of 57 patients treated, 48 percent ...

Researchers identify a potential new approach to treat HER2 positive breast cancer

August 30, 2018
Researchers at Mayo Clinic have identified an important new pathway by which HER2 positive breast cancers grow and have discovered that a dietary supplement called cyclocreatine may block the growth of HER2 positive breast ...

Study finds breast cancer driver, HER2, in 3 percent of lung cancers

July 27, 2017
The Lung Cancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced-stage lung cancer had mutations in the gene HER2. Seventy-one ...

Adjuvant Trastuzumab did not improve outcomes for patients with HER2-low breast cancer

December 6, 2017
Adding trastuzumab (Herceptin) to standard adjuvant chemotherapy did not improve invasive disease–free survival for patients with early-stage breast cancer found to have low levels of HER2, as defined as immunohistochemistry ...

New lab study reveals how breast cancer drug can accelerate cancer cell growth

May 1, 2018
The breast cancer drug lapatinib which is designed to shrink tumours can sometimes cause them to grow in the lab, according to a new study published in eLife. By understanding the molecular basis of this phenomenon, scientists ...

Recommended for you

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

An integrated approach to finding new treatments for breast cancer

December 12, 2018
Unraveling the complexity of cancer biology can lead to the identification new molecules involved in breast cancer and prompt new avenues for drug development. And proteogenomics, an integrated, multipronged approach, seems ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.